In conclusion, the above findings further demonstrate that TIM3 plays an important role in AML pathogenesis and that combining multiple targets (e.g., TIM-3 with other leukemia-associated molecules) to inhibit LSC exhibits stronger anti-leukemic activity than a single target (27). The gene discussed is HAVCR2; the disease is leukemia.